SEARL in a notice informed that it has concluded an exclusive licensing & supply agreement with Livzon Mapharm Inc for the “recombinant novel coronavirus vaccine(V-01)’ which also covers manufacturing transition of (V-01) in Pakistan.
SEARL has concluded an exclusive licensing & supply agreement with Livzon Mapharm Inc